These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
895 related articles for article (PubMed ID: 36386454)
1. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma. Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454 [TBL] [Abstract][Full Text] [Related]
2. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs. Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187 [TBL] [Abstract][Full Text] [Related]
3. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma. Ma C; Li F; Gu Z; Yang Y; Qi Y Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938 [No Abstract] [Full Text] [Related]
4. A cuproptosis-related lncRNAs risk model to predict prognosis and guide immunotherapy for lung adenocarcinoma. Li Q; Wang T; Zhu J; Zhang A; Wu A; Zhou Y; Shi J Ann Transl Med; 2023 Mar; 11(5):198. PubMed ID: 37007546 [TBL] [Abstract][Full Text] [Related]
5. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma. Xu M; Mu J; Wang J; Zhou Q; Wang J Front Oncol; 2022; 12():961213. PubMed ID: 35965536 [TBL] [Abstract][Full Text] [Related]
6. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma. Wang F; Lin H; Su Q; Li C World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740 [TBL] [Abstract][Full Text] [Related]
7. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma. Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612 [TBL] [Abstract][Full Text] [Related]
8. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer. Pan Y; Zhang Q; Zhang H; Kong F Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of cuproptosis-related lncRNAs to predict prognosis and immune infiltration characteristics in colorectal cancer. Zhu Z; Zhao Q; Li S; Weng J; Guo T; Zhu C; Xu Y Front Genet; 2022; 13():984743. PubMed ID: 36467996 [No Abstract] [Full Text] [Related]
10. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma. Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708 [TBL] [Abstract][Full Text] [Related]
11. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia. Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F Front Oncol; 2022; 12():966920. PubMed ID: 36276132 [TBL] [Abstract][Full Text] [Related]
12. Characterization of cuproptosis-related lncRNA landscape for predicting the prognosis and aiding immunotherapy in lung adenocarcinoma patients. Sun X; Song J; Lu C; Sun X; Yue H; Bao H; Wang S; Zhong X Am J Cancer Res; 2023; 13(3):778-801. PubMed ID: 37034212 [TBL] [Abstract][Full Text] [Related]
13. Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis. Gao C; Kong N; Zhang F; Zhou L; Xu M; Wu L BMC Bioinformatics; 2022 Aug; 23(1):327. PubMed ID: 35941550 [TBL] [Abstract][Full Text] [Related]
14. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs. Zhang X; Ye Z; Xiao G; He T Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773 [TBL] [Abstract][Full Text] [Related]
15. A novel cuproptosis-related lncRNA signature to predict prognosis and immune landscape of lung adenocarcinoma. Wang X; Jing H; Li H Transl Lung Cancer Res; 2023 Feb; 12(2):230-246. PubMed ID: 36895935 [TBL] [Abstract][Full Text] [Related]
16. Cuproptosis-related LncRNAs are potential prognostic and immune response markers for patients with HNSCC via the integration of bioinformatics analysis and experimental validation. Zhou L; Cheng Q; Hu Y; Tan H; Li X; Wu S; Zhou T; Zhou J Front Oncol; 2022; 12():1030802. PubMed ID: 36620545 [TBL] [Abstract][Full Text] [Related]
17. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia. Zhu Y; He J; Li Z; Yang W BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692 [TBL] [Abstract][Full Text] [Related]
18. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma. Liu Y; Jiang J Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878 [TBL] [Abstract][Full Text] [Related]
19. Cuproptosis-Related lncRNAs are Biomarkers of Prognosis and Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. Yang L; Yu J; Tao L; Huang H; Gao Y; Yao J; Liu Z Front Genet; 2022; 13():947551. PubMed ID: 35938003 [No Abstract] [Full Text] [Related]
20. A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma. Zhang W; Wang H; Wang W; Xue H; Qiao M; Song L; Wang S; Ren Z; Ma Z Anal Cell Pathol (Amst); 2022; 2022():4673514. PubMed ID: 36588797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]